-

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.

The webcast and conference call will be hosted by Carrie Cox, Organon’s Executive Board Chair; Joe Morrissey, Interim Chief Executive Officer; and Matt Walsh, Chief Financial Officer.

IPR&D and Milestones

The company will not record any milestone expense in the third quarter of 2025.

Accessing Third Quarter 2025 Financial Results Webcast

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144 (U.S. and Canada Toll-Free) or (646) 968-2525 and using the access code Conference ID: 1036555#.

About Organon

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Contacts

Organon Media Contacts:

Felicia Bisaro
(646) 703-1807

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB

Release Summary
Organon to announce Q3 2025 financial results on November 10, 2025.
Release Versions

Contacts

Organon Media Contacts:

Felicia Bisaro
(646) 703-1807

Organon Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Social Media Profiles
More News From Organon & Co.

Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI

JERSEY CITY, N.J.--(BUSINESS WIRE)--ACAAI- new pooled post-hoc analysis of VTAMA (tapinarof) cream, 1% demonstrates consistent response for atopic dermatitis disease severity and itch...

New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System

JERSEY CITY, N.J.--(BUSINESS WIRE)--Analysis of 16,000+ VA patients switching to HADLIMA from HUMIRA showed a 1.3% switchback rate and generated $132M in estimated savings....

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon VTAMA (tapinarof) cream, 1%, new pooled post-hoc analysis of Phase 3 data will be presented at 2026 ACAAI Scientific Meeting....
Back to Newsroom